Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Pembrolizumab in BRCA-Mutated TNBC
NCT05485766Phase 2Recruiting
- Sponsor
- Okayama University
- Start
- Jul 2024
- Primary completion
- Jun 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Okayama University. Primary endpoint: Pathological Complete Response Rate (ypT0/Tis ypN0). Started Jul 2024; status: recruiting.
02
Drugs
olaparibpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05485766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05485766.